These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 12413427)

  • 41. Ribozyme gene therapy for autosomal dominant retinal disease.
    Hauswirth WW; LaVail MM; Flannery JG; Lewin AS
    Clin Chem Lab Med; 2000 Feb; 38(2):147-53. PubMed ID: 10834402
    [TBL] [Abstract][Full Text] [Related]  

  • 42. 3'-End modification of the adenoviral VA1 gene affects its expression in human cells: consequences for the design of chimeric VA1 RNA ribozymes.
    Barcellini-Couget S; Fenard D; Bertrand E; Singer RH; Lefebvre JC; Doglio A
    Antisense Nucleic Acid Drug Dev; 1998 Oct; 8(5):379-90. PubMed ID: 9826265
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bacterial virus phi29 pRNA as a hammerhead ribozyme escort to destroy hepatitis B virus.
    Hoeprich S; Zhou Q; Guo S; Shu D; Qi G; Wang Y; Guo P
    Gene Ther; 2003 Aug; 10(15):1258-67. PubMed ID: 12858191
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A three-nucleotide helix I is sufficient for full activity of a hammerhead ribozyme: advantages of an asymmetric design.
    Tabler M; Homann M; Tzortzakaki S; Sczakiel G
    Nucleic Acids Res; 1994 Sep; 22(19):3958-65. PubMed ID: 7937118
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Examination of the catalytic fitness of the hammerhead ribozyme by in vitro selection.
    Tang J; Breaker RR
    RNA; 1997 Aug; 3(8):914-25. PubMed ID: 9257650
    [TBL] [Abstract][Full Text] [Related]  

  • 46. In vivo RNA transcript-releasing plasmid possessing a universal pseudo-terminator by means of artificial ribozymes.
    Ohme-Takagi M; Shinshi H; Oda M; Uchimaru T; Nishikawa S; Taira K
    Nucleic Acids Symp Ser; 1990; (22):49-50. PubMed ID: 1714571
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Assaying synthetic ribozymes in plants: high-level expression of a functional hammerhead structure fails to inhibit target gene activity in transiently transformed protoplasts.
    Mazzolini L; Axelos M; Lescure N; Yot P
    Plant Mol Biol; 1992 Nov; 20(4):715-31. PubMed ID: 1450386
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Inhibition of luciferase expression by synthetic hammerhead ribozymes and their cellular uptake.
    Bramlage B; Alefelder S; Marschall P; Eckstein F
    Nucleic Acids Res; 1999 Aug; 27(15):3159-67. PubMed ID: 10454613
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Inhibition of HIV-1 in human T-lymphocytes by retrovirally transduced anti-tat and rev hammerhead ribozymes.
    Zhou C; Bahner IC; Larson GP; Zaia JA; Rossi JJ; Kohn EB
    Gene; 1994 Nov; 149(1):33-9. PubMed ID: 7958986
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Production of Homogeneous Recombinant RNA Using a tRNA Scaffold and Hammerhead Ribozymes.
    Nelissen FH; Heus HA; Wijmenga SS
    Methods Mol Biol; 2015; 1316():33-44. PubMed ID: 25967051
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Designing ribozymes for the inhibition of gene expression.
    Bramlage B; Luzi E; Eckstein F
    Trends Biotechnol; 1998 Oct; 16(10):434-8. PubMed ID: 9807841
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Minimized hammerhead ribozymes.
    McCall MJ; Hendry P; Lockett TJ
    Methods Mol Biol; 1997; 74():151-9. PubMed ID: 9204430
    [No Abstract]   [Full Text] [Related]  

  • 53. Structure-function relationships of hammerhead ribozymes: from understanding to applications.
    Sigurdsson ST; Eckstein F
    Trends Biotechnol; 1995 Aug; 13(8):286-9. PubMed ID: 7662303
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pseudoknot interaction-mediated activation of type I hammerhead ribozyme: a new class of gene-therapeutic agents.
    Kuriyama M; Kondo Y; Tanaka Y
    Nucleosides Nucleotides Nucleic Acids; 2014; 33(7):466-80. PubMed ID: 24972011
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A cellular high-throughput screening approach for therapeutic trans-cleaving ribozymes and RNAi against arbitrary mRNA disease targets.
    Yau EH; Butler MC; Sullivan JM
    Exp Eye Res; 2016 Oct; 151():236-55. PubMed ID: 27233447
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ribozyme-mediated specific gene replacement of the alpha1-antitrypsin gene in human hepatoma cells.
    Ozaki I; Zern MA; Liu S; Wei DL; Pomerantz RJ; Duan L
    J Hepatol; 1999 Jul; 31(1):53-60. PubMed ID: 10424283
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Expression of hammerhead ribozymes by retroviral vectors to inhibit HIV-1 replication: comparison of RNA levels and viral inhibition.
    Zhou C; Bahner I; Rossi JJ; Kohn DB
    Antisense Nucleic Acid Drug Dev; 1996; 6(1):17-24. PubMed ID: 8783792
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Development of ribozymes for gene therapy.
    Sullivan SM
    J Invest Dermatol; 1994 Nov; 103(5 Suppl):85S-89S. PubMed ID: 7963690
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Generation of a ribozyme-adenoviral vector against K-ras mutant human lung cancer cells.
    Zhang YA; Nemunaitis J; Tong AW
    Mol Biotechnol; 2000 May; 15(1):39-49. PubMed ID: 10911621
    [TBL] [Abstract][Full Text] [Related]  

  • 60. NMR spectroscopic characterization of a model RNA duplex reflecting the core sequence of hammerhead ribozymes.
    Hattori Y; Yamanaka D; Morioka S; Yamaguchi T; Tomonari H; Kojima C; Tanaka Y
    Nucleosides Nucleotides Nucleic Acids; 2018; 37(7):383-396. PubMed ID: 29953330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.